Paul J Yazaki Selected Research

Immunoglobulin Fragments

9/2017	Synthesis, Positron Emission Tomography Imaging, and Therapy of Diabody Targeted Drug Lipid Nanoparticles in a Prostate Cancer Murine Model.
4/2017	PET imaging of 64Cu-DOTA-scFv-anti-PSMA lipid nanoparticles (LNPs): Enhanced tumor targeting over anti-PSMA scFv or untargeted LNPs.
3/2013	A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance.
2/2008	Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein.
1/2007	Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy.
1/2005	Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.
8/2004	Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer.
4/2004	Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting.
12/2003	124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paul J Yazaki Research Topics

Disease

35	Neoplasms (Cancer) 12/2022 - 12/2003
8	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 01/2003
7	Neoplasm Metastasis (Metastasis) 09/2020 - 12/2003
5	Prostatic Neoplasms (Prostate Cancer) 02/2020 - 06/2011
3	Colonic Neoplasms (Colon Cancer) 09/2020 - 10/2017
2	Breast Neoplasms (Breast Cancer) 12/2022 - 12/2009
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 12/2018
1	Stomach Neoplasms (Stomach Cancer) 12/2021
1	Multiple Myeloma 01/2021
1	Ovarian Neoplasms (Ovarian Cancer) 01/2021
1	Body Weight (Weight, Body) 02/2020
1	Residual Neoplasm 02/2020
1	Adenocarcinoma 01/2020
1	Myeloid Leukemia (Leukemia, Myelocytic) 12/2019
1	Virus Diseases (Viral Diseases) 01/2015
1	Colitis 01/2015
1	Carcinoma (Carcinomatosis) 06/2011
1	Hematologic Neoplasms (Hematological Malignancy) 12/2003

Drug/Important Bio-Agent (IBA)

14	AntigensIBA 12/2022 - 12/2003
12	AntibodiesIBA 02/2022 - 12/2003
11	Carcinoembryonic AntigenIBA 12/2022 - 04/2004
9	Immunoglobulin FragmentsIBA 09/2017 - 12/2003
4	Radioisotopes (Radionuclides)IBA 01/2021 - 12/2003
4	Monoclonal AntibodiesIBA 09/2020 - 05/2004
4	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 04/2017 - 07/2010
3	Glycoproteins (Glycoprotein)IBA 01/2021 - 07/2010
3	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2007
3	Sulfhydryl Compounds (Thiols)IBA 04/2017 - 01/2008
2	1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA 01/2022 - 01/2021
2	Tumor Biomarkers (Tumor Markers)IBA 01/2022 - 01/2021
2	Coloring Agents (Dyes)IBA 09/2020 - 10/2017
2	tumor-associated antigen 72IBA 09/2020 - 01/2020
2	Immunoglobulin G (IgG)IBA 01/2020 - 07/2010
2	Fluorescent Dyes (Fluorescent Probes)IBA 12/2018 - 04/2018
2	Pharmaceutical PreparationsIBA 09/2017 - 04/2017
2	Lipid NanoparticlesIBA 09/2017 - 04/2017
2	Cysteine (L-Cysteine)FDA Link 04/2017 - 01/2004
2	LigandsIBA 04/2017 - 06/2011
1	InterferonsIBA 12/2022
1	Interleukin-2 (IL2)IBA 12/2022
1	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 12/2022
1	RNA (Ribonucleic Acid)IBA 02/2022
1	SolutionsIBA 02/2022
1	Muromonab-CD3 (Muromonab CD3)FDA Link 02/2022
1	(2,4- dihydroxy- 5- isopropylphenyl)- (5- (4- methylpiperazin- 1- ylmethyl)- 1,3- dihydroisoindol- 2- yl)methanoneIBA 01/2022
1	Therapeutic UsesIBA 01/2022
1	ferroceneIBA 01/2022
1	daratumumabIBA 01/2021
1	IRDye800IBA 09/2020
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 02/2020
1	LipidsIBA 01/2020
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2020
1	Cell Surface ReceptorsIBA 12/2019
1	Green Fluorescent ProteinsIBA 04/2018
1	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2017
1	auristatinIBA 09/2017
1	maleimideIBA 04/2017
1	MicellesIBA 04/2017
1	PolymersIBA 04/2017
1	EstersIBA 04/2017
1	1,2-distearoylphosphatidylethanolamine (DSPE)IBA 04/2017
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 04/2016
1	Interleukin-6 (Interleukin 6)IBA 04/2016
1	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 04/2016
1	MucinsIBA 01/2015
1	CTLA-4 AntigenIBA 01/2015
1	CytokinesIBA 01/2015
1	CEACAM1 ProteinIBA 01/2015
1	Bispecific AntibodiesIBA 03/2013
1	Membrane Proteins (Integral Membrane Proteins)IBA 06/2011
1	IsotopesIBA 04/2011
1	Lysine (L-Lysine)FDA Link 04/2011
1	Immunoglobulins (Immunoglobulin)IBA 12/2009
1	Trastuzumab (Herceptin)FDA Link 12/2009
1	AlbuminsIBA 02/2008
1	Humanized Monoclonal AntibodiesIBA 01/2008
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2006
1	indium- 111- 1,4,7,10- tetraazacyclododecane- 1,4,7,10- tetraacetic acidIBA 07/2005
1	Indicators and Reagents (Reagents)IBA 05/2004
1	DisulfidesIBA 01/2004
1	Fluorouracil (Carac)FDA LinkGeneric 12/2003

Therapy/Procedure

12	Therapeutics 12/2022 - 01/2003
7	Radioimmunotherapy 01/2022 - 12/2003
3	Immunotherapy 12/2022 - 12/2009
2	Drug Therapy (Chemotherapy) 08/2004 - 12/2003
1	Castration 02/2020
1	Aftercare (After-Treatment) 02/2020
1	Computer-Assisted Surgery (Image Guided Surgery) 12/2018
1	Laparotomy 10/2017
1	Neoadjuvant Therapy 08/2004
1	Radiotherapy 12/2003